Results 91 to 100 of about 1,651 (123)

Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials. [PDF]

J Antimicrob Chemother
Werth BJ, Zhang R, Barreras Beltran IA, Penewit K, Waalkes A, Holmes EA, Salipante SJ, Xu L.   +7 more
europepmc   +1 more source

Editorial: Pharmacoepidemiology in infectious diseases. [PDF]

Front Antibiot
Henriquez-Camacho C.
europepmc   +1 more source

Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections. [PDF]

Infection
Karačić J, Grosse M, Pfarr K, Schiefer A, Schneider T, Hoerauf A, Karačić S, Parčina M, Hischebeth G, Fröschen FS, Bierbaum G.   +10 more
europepmc   +1 more source

Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium ? [PDF]

Clin Orthop Relat Res
Krsak M, Morrisette T, Damioli L, Flues B, Liu EW, Zhou AY, Msdi AS, McLeod C, Akundi S, Redell M, Molina KC.   +10 more
europepmc   +1 more source

Long-Term Suppressive Antimicrobial Therapy in Prosthetic Vascular Graft Infection: A Retrospective Evaluation of a Cohort of Patients Enrolled at Tor Vergata Hospital in Rome. [PDF]

Open Forum Infect Dis
Imeneo A, Zaçe D, Oddi FM, Alessio G, Ferrari L, Mulas T, Crea A, Malagnino V, Ascoli Marchetti A, Ippoliti A, Iannetta M, Sarmati L.   +11 more
europepmc   +1 more source

UK Antimicrobial Registry: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland. [PDF]

JAC Antimicrob Resist
Goswami C, Turgal E, Mueller T, Bennie M, Parr R, Jones GT, Seaton RA, Jenkins D, Baltas I, Sneddon J, Sandoe JAT, Garraghan F, Brown NM, Macfarlane GJ, Kurdi A.   +14 more
europepmc   +1 more source

Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? [PDF]

J Antimicrob Chemother
MacPhail A, Attwood LO, Rogers BA.
europepmc   +1 more source

Challenges in monitoring vancomycin in outpatient parenteral antimicrobial therapy: opportunities for mitigation utilizing OSHA's framework for mitigating workplace hazards. [PDF]

Antimicrob Steward Healthc Epidemiol
Regli DC, Warner S, Wilcox E, Zimmerman J, Bittner MJ.   +4 more
europepmc   +1 more source

Stealth MRSA: a diagnostic pitfall in invasive <i>Staphylococcus aureus</i> infection. [PDF]

ASM Case Rep
Karre TA, Kotula RJ, Goering RV.
europepmc   +1 more source

Albumin and Other Plasma Proteins in Pediatric Patients: What, When, and How Much They Influence Antimicrobial Pharmacology. [PDF]

J Pediatr Pharmacol Ther
Angelini J, Russiani F, Ferin S, Flammini S, Tascini C, Roberts JA, Baraldo M, Giuliano S.   +7 more
europepmc   +1 more source